P atients with nonvalvular atrial fibrillation (AF) and renal dysfunction face high risks of both thromboembolism and bleeding during antithrombotic therapy. [1] [2] [3] [4] In these patients, anticoagulants are not always administered because of concern that bleeding may outweigh the potential benefit. 5, 6 Although anticoagulation with warfarin or the novel anticoagulants (NOACs), which have been rapidly adopted into routine clinical practice, 7 without excessive bleeding risk can be achieved in those with moderately reduced baseline renal function, [8] [9] [10] patients exhibit a decline in renal function over time that appears to be greater in those taking warfarin. 11 However, it is unknown whether outcomes differ among patients with worsening renal function (WRF) compared with those with stable renal function (SRF) while taking a NOAC compared with warfarin.
Rivaroxaban is a direct factor Xa inhibitor with a rapid onset and offset of action after oral administration that is metabolized predominantly by the liver, with approximately one third excreted unchanged in the urine. 12, 13 As renal function declines, rivaroxaban plasma concentrations and the area under the plasma concentration-time curve increase, but these increases have only a moderate effect on rivaroxaban clearance. 14, 15 The ROCKET AF trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) compared rivaroxaban with warfarin for the prevention of all stroke and systemic embolism events in 14 264 patients with AF. 16 Patients with moderate renal dysfunction, defined by a creatinine clearance (CrCl) of 30 to 49 mL/min at baseline, received a reduced dose of rivaroxaban (15 once mg daily). There were no changes in the rivaroxaban dose after the baseline evaluation unless CrCl fell below 25 mL/min, at which point study medication was stopped.
MethOds
The design and main results of the ROCKET AF trial have been reported previously. 16, 17 In brief, this was a multicenter, randomized, double-blind, double-dummy, event-driven trial comparing fixed-dose rivaroxaban (20 or 15 mg once daily in patients with CrCl 30-49 mL/min at baseline) with adjusted-dose warfarin (target international normalized ratio, 2.0-3.0] for the prevention of all stroke (ischemic or hemorrhagic) or systemic embolism events. To maintain blinding, the Alere HemoSense point-of-care device was used to generate real international normalized ratios or sham values. The doses of warfarin and matching placebo tablets were adjusted on the basis of these values. The study was approved by ethics/institutional review boards at all participating sites, and all patients provided written informed consent.
study Participants
Complete inclusion and exclusion criteria have been published. 17 Briefly, patients with electrocardiographically documented nonvalvular AF at moderate to high risk of stroke were recruited at 1178 participating sites in 45 countries. Elevated stroke risk was indicated by a history of stroke, transient ischemic attack, or systemic embolism or at least 2 of the following risk factors: heart failure or left ventricular ejection fraction ≤35%, hypertension, age ≥75 years, or diabetes mellitus (CHADS 2 score ≥2). Those with a high risk for bleeding (including previous intracerebral bleeding, surgical trauma within 30 days, and gastrointestinal bleeding within 6 months) were excluded.
From December 18, 2006 , through June 17, 2009 , a total of 14 236 patients underwent randomization and received at least 1 dose of randomized study drug. The following patients were then excluded from this analysis: those with missing screening creatinine measurements (n=13), those with no postrandomization creatinine measurements (n=1025), and those whose postrandomization measurements occurred after discontinuation of study drug (n=586). This resulted in a final analysis population of 12 612 patients with at least 1 postrandomization creatinine measurement during the on-treatment period (patients randomized to either warfarin or rivaroxaban).
renal Function and dose assignment
The study protocol required that patients receive a minimum of 4 serum creatinine measurements: at screening, 24 weeks after randomization, 52 weeks after randomization, and the end of the study or at early study drug discontinuation. Additional serum creatinine measurements could be performed as part of standard of care, and these values were also recorded. CrCl was determined by the Cockcroft-Gault formula. 18 Patients with CrCl <30 mL/min were excluded from ROCKET AF. Patients with moderate renal insufficiency (CrCl, 30-49 mL/min) have clinical Perspective
What is new?
• Although the novel anticoagulants have been rapidly adopted into routine clinical practice, it is unknown whether outcomes differ among atrial fibrillation patients with worsening renal function compared with those with stable renal function while taking a novel anticoagulant versus warfarin.
• The results of the present study demonstrate not only that it is possible to safely anticoagulate patients with worsening renal function without excessive bleeding but also that rivaroxaban is an attractive alternative to warfarin in patients with worsening renal function or those at risk for worsening renal function.
What are the clinical implications?
• This study fills an important knowledge gap that
has not yet been addressed in the pivotal novel anticoagulant trials or large registries, and it informs clinical decision making for the management of this important subgroup of patients with atrial fibrillation who are at high risk for both thromboembolism and bleeding.
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higher plasma levels of rivaroxaban (maximal serum concentration increased by 12% and area under the plasma concentration-time curve increased by 52%) compared with those with preserved renal function. 15 Patients' doses of the study drug were assigned on the basis of CrCl during the screening visit: 20 mg once daily for patients with CrCl ≥50 mL/min or 15 mg once daily for patients with CrCl of 30 to 49 mL/min at baseline. Patients with CrCl <25 mL/min on 2 consecutive measurements were required to discontinue study drug. 17 However, there were otherwise no dose adjustments after baseline for changing CrCl.
definitions: srF Versus WrF
The association between WRF and adverse clinical outcomes has been extensively documented in the heart failure population. 19, 20 WRF, evaluated as a time-dependent covariate in Cox proportional hazards models, was defined as a decrease of >20% in CrCl from the screening CrCl measurement at any time during the study period. This definition was recently used in several secondary analyses of randomized, controlled trials in patients with heart failure, [21] [22] [23] and it may be more accurate than an absolute increase in serum creatinine (ie, ≥0.3 mg/ dL), which could be biased by baseline renal function. 24 SRF was defined as the absence of WRF at any time. For counting of events and within models, once patients entered the WRF group, they remained there for the rest of the followup period. Because the Cockcroft-Gault formula was used in ROCKET AF to calculate CrCl and to determine trial eligibility, dose adjustment, and study drug cessation, we prospectively determined that Cockcroft-Gault would be the primary modality used to measure CrCl in the present study. However, because the definition of WRF could differ, depending on the manner in which CrCl is calculated, we also performed sensitivity analyses using the MDRD (Modification of Diet in Renal Disease) 25 and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 26 formulas.
Outcomes
The primary efficacy end point was the composite of all stroke (both ischemic and hemorrhagic) and systemic embolism. Secondary end points included the composite of stroke, non-central nervous system systemic embolism, cardiovascular death, and myocardial infarction, as well as individual components of the composite end points. The principal safety end point was the composite of major and nonmajor clinically relevant (NMCR) bleeding events.
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Bleeding events involving the central nervous system meeting the definition of stroke were adjudicated as hemorrhagic strokes and included in both the primary efficacy and safety end points. An independent clinical events committee applied the protocol definitions and adjudicated all suspected stroke, systemic embolism, myocardial infarction, death, and bleeding events contributing to the prespecified efficacy and safety end points. All outcomes were measured from the time of the first follow-up creatinine measurement (usually at 24 weeks after randomization) to the time of the last dose of study drug plus 2 days. Events were counted in the SRF group if they occurred before WRF was documented; in the WRF group, events were counted if they occurred afterward.
statistical analysis
Serum creatinine and CrCl were compared between the randomized treatment groups by use of Wilcoxon rank-sum tests. Baseline characteristics were compared between SRF and WRF patients by use of Wilcoxon rank-sum tests for continuous variables and Pearson χ 2 tests for categorical variables. Event rates are shown as events per 100 patient-years with 95% Poisson confidence intervals (CIs). Association of WRF with risk of outcomes was assessed with Cox proportional hazards models, with WRF included as a time-dependent covariate. All models were adjusted for other predictors of each outcome established in the full ROCKET cohort. The following variables were used in the safety end point models: randomized treatment, age, sex, geographic region, previous stroke/ transient ischemic attack, anemia, previous gastrointestinal bleed, chronic obstructive pulmonary disease, diastolic blood pressure, platelets, albumin, and previous vitamin K antagonist, aspirin, or thienopyridine use. The following variables were used in the efficacy end point models: randomized treatment, age, sex, body mass index, geographic region, paroxysmal AF, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease (myocardial infarction, peripheral artery disease, or carotid occlusive disease), congestive heart failure, hypertension, chronic obstructive pulmonary disorder, diastolic blood pressure, heart rate, and alcohol use. Models also included a term for the interaction between WRF and randomized treatment. For models comparing WRF by baseline CrCl category, variables were similar except for the addition of a term for the screening CrCl subgroup and replacement of the interaction term with one for the interaction of screening CrCl with WRF. In addition, outcomes were examined by the use of models that considered absolute magnitude of CrCl change from screening as a continuous variable, also in a time-dependent manner. With the use of restricted cubic splines, change in CrCl was first evaluated for the linearity of its relationship with each outcome (using only the first CrCl value) and was found to be linear in all cases. Therefore, for all outcomes, CrCl decrease was fit as a straight line in the final models, using all follow-up CrCl values. Increases in CrCl from screening were set to a value of 0 (ie, the models estimated risk relationships only for degrees of decrease in CrCl from screening).
Efficacy end point models omitted patients from 1 site that violated good clinical practice (n=82). From all models, risk relationships are expressed as hazard ratios (HRs) with 95% CIs. All statistical analyses were performed with SAS software (version 9.4, SAS Institute).
results
Patient characteristics
The final analysis population included 12 612 patients, of whom 9292 (73.7%) had SRF and 3320 (26.3%) had WRF. Rates of WRF, as defined by a reduction in CrCl ≥20% while on treatment, did not differ between the 6253 patients randomized to rivaroxaban (26%, n=1632) and the 6359 patients randomized to warfarin (27%, n=1688; P=0.09; Table 1 ). However, there was a small, statistically significant decline in mean±SD CrCl among patients receiving warfarin (−4.3±14.6 mL/min) compared with patients receiving rivaroxaban (−3.5±15.1 mL/min; P<0.001). The overall population had a median age of 73 years and a mean CHADS 2 score of 3.5±0.9, and 64% were previously treated with a vitamin K antagonist. Baseline characteristics were generally similar between patients who maintained SRF and patients with WRF, with some exceptions, including risk factors for and history of thromboembolism (Table 2) . Compared with patients with SRF, patients with WRF experienced a greater incidence of hypertension (93% versus 90%), diabetes mellitus (43% versus 39%), previous myocardial infarction (18% versus 16%), and congestive heart failure (65% versus 61%) but were less likely to have an actual history of previous stroke, transient ischemic attack, or non-central nervous system embolism (52% versus 56%).
The type and dose of anticoagulant in patients with SRF (warfarin, 51%; rivaroxaban 20 mg, 39%; rivaroxaban 15 mg, 10%) were similar to those in patients with WRF (warfarin, 49%; rivaroxaban 20 mg, 41%; rivaroxaban 15 mg, 10%). A total of 62 patients discontinued study drug permanently because of renal failure or renal impairment (35 for rivaroxaban and 27 for warfarin).
Outcomes according to change in renal Function
There was no statistically significant difference in the primary efficacy outcome (stroke or non-central nervous system embolism) between patients with WRF and those with SRF (adjusted HR, 1.25; 95% CI, P=0.19) . The rates of myocardial infarction were similar between patients with WRF and SRF. However, WRF patients had a higher incidence of vascular death (adjusted HR, 1.47; 95% CI, 1.05-2.06; P=0.026); the composite end point of stroke, systemic embolism, vascular death, or myocardial infarction (adjusted HR, 1.40; 95% CI, 1.13-1.73; P=0.0023); and all-cause mortality (adjusted HR, 1.49; 95% CI, 1.12-1.98; P=0.0067; Table 3 ). There was no difference in the primary safety end point of International Society on Thrombosis and Haemostasis (ISTH) major or NMCR bleeding between the WRF and SRF patients (adjusted HR, 1.05; 95% CI, 0.90-1.21; P=0.55). We also found no difference in any of the bleeding subgroups and no difference in gastrointestinal bleeding between WRF and SRF patients (adjusted HR, 1.18; 95% CI, 0.78-1.77; P=0.44). There was no significant interaction between baseline renal impairment (CrCl <50 mL/min) and WRF on any outcome (Table I in the online-only Data Supplement). There was no difference in outcomes whether the magnitude of WRF was small (<10 mL/min lower than screening CrCl) or large (≥10 mL/min lower than screening CrCl), except for a higher incidence of all-cause mortality among patients with the greatest decrease in CrCl (adjusted HR for each 10-mL/ min CrCl decrease, 1.18; 95% CI, 1.03-1.36; P=0.019; Table II in the online-only Data Supplement).
Outcomes according to randomized treatment assignment and change in renal Function
WRF patients randomized to receive rivaroxaban had a reduction in stroke or systemic embolism compared with Continuous variables are shown as median (25th, 75th percentile) except when noted. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CHADS 2 , congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and history of stroke or transient ischemic attack; CNS, central nervous system; COPD, chronic obstructive pulmonary disorder; CrCl, creatinine clearance; SCr, serum creatinine; SRF, stable renal function; TIA, transient ischemic attack; and WRF, worsening renal function.
WRF patients randomized to receive warfarin (1.54 versus 3.25 events per 100 patient-years for patients taking rivaroxaban versus warfarin) that was not seen in SRF patients (1.80 versus 1.83 events per 100 patient-years for patients taking rivaroxaban versus warfarin; P=0.050 for interaction; Figure 1 ). In those with WRF, there was no significant difference in major or NMCR bleeding between those randomized to warfarin and those randomized to rivaroxaban. WRF patients randomized to receive rivaroxaban had a greater incidence of a hemoglobin decrease ≥2 g/dL (3.56 versus 1.85 events per 100 patient-years for patients taking rivaroxaban versus warfarin) that was not seen in SRF patients (2.22 versus 2.19 events per 100 patient-years for patients taking rivaroxaban versus warfarin; P=0.047 for interaction). Similarly, WRF patients randomized to receive rivaroxaban had a greater incidence of gastrointestinal bleeding that was not seen in SRF patients (3.21 versus 1.28 events per 100 patient-years for patients taking rivaroxaban versus warfarin; P=0.02 for interaction). However, there was no difference between patients with WRF and SRF for major or NMCR bleeding (P=0.61 for interaction between patients randomized to warfarin and rivaroxaban) or intracerebral hemorrhage (P=0.67 for interaction). We explored the interaction of assigned treatment and WRF with WRF expressed as a continuous variable for the end points of stroke or systemic embolism (Figure 2A ) and major or NMCR bleeding ( Figure 2B ) by magnitude of decrease in CrCl from screening. Consistent with the above findings, the greater the percent of CrCl decrease from screening, the greater the increase in stroke or systemic embolism in patients randomized to warfarin. In contrast, among patients receiving rivaroxaban, event rates were similar regardless of the percent of CrCl decrease. Bleeding rates were consistent across arms and the full range of decreasing CrCl, which was also consistent with the above findings.
We also performed sensitivity analyses using the MDRD and CKD-EPI formulas to define WRF (Tables III  and IV in the online-only Data Supplement). The results were consistent with the overall pattern found with the Cockcroft-Gault formula, with some exceptions. With the CKD-EPI formula, there was a trend, but no longer a significant interaction, for stroke or systemic embolism for WRF patients randomized to rivaroxaban (P=0.28 for interaction) and hemoglobin decrease ≥2 g/dL (P=0.11 for interaction). The interaction for myocardial infarction was significant (P=0.034), but this estimate in WRF patients is based on only 20 events.
discussiOn
The overall aim of the present study was to determine whether outcomes differ among patients with WRF on rivaroxaban compared with warfarin. Warfarin was associated with a small but significant reduction in CrCl compared with rivaroxaban. Compared with patients with SRF, patients with WRF experienced an increased incidence of vascular death; the composite end point of stroke, systemic embolism, vascular death, or myocardial infarction; and all-cause mortality. We also found that among patients with WRF, rivaroxaban was associated with significantly lower rates of the primary end point of stroke and systemic embolism and the composite end point of stroke, systemic embolism, vascular death, or myocardial infarction compared with warfarin; however, this was without an increase in the composite bleeding end point. This is the first study to demonstrate a differential on-treatment effect of any NOAC compared with warfarin in patients with WRF. Changes in renal function are frequently observed in clinical practice and often complicate medical management. In this cohort, more than one quarter of patients experienced a significant decline in renal function. Although baseline renal function was required for inclusion or dosing in trials evaluating the NOACs, protocols did not specify whether WRF alone should lead to study drug discontinuation or dose adjustment. 17, 28, 29 A recent study from the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) found that a decline in renal function was greater in those taking warfarin compared with those taking dabigatran, 11 which is consistent with our results. Our study extends these findings to a factor Xa inhibitor and assesses outcomes between warfarin and NOAC therapy among patients with WRF, which has not been previously reported in the literature.
This study has several important implications. First, in showing that the reduction in stroke or systemic embolism among WRF patients on rivaroxaban compared with warfarin was without any major difference in major or NMCR bleeding, these data suggest that rivaroxaban may be a better choice of anticoagulant for patients with AF who experience on-treatment WRF. This is particularly important because we also found that experiencing WRF is relatively frequent among patients with CI indicates confidence interval; hbg, hemoglobin; ICH, intracranial hemorrhage; MI, myocardial infarction; NMCR, nonmajor clinically relevant; pt-years; patient-years; SE, systemic embolism; SRF, stable renal function; V-death, vascular death; and WRF, worsening renal function.
July 5, 2016
Circulation. AF taking anticoagulants and that these patients are at greater risk for adverse events compared with patients with SRF. Second, these results extend previous findings that patients with renal dysfunction are at increased risk of thromboembolism 30 and that patients with moderate renal impairment had higher absolute rates of stroke and systemic embolism and major and NMCR bleeding than those with CrCl ≥50 mL/min, regardless of whether they were treated with warfarin or with rivaroxaban. 9 Furthermore, renal dysfunction itself is associated with a lower time in therapeutic range during warfarin administration compared with normal renal function. 31 These results also extend previous analyses finding that dose adjustment (from 20-15 mg rivaroxaban daily) among patients with moderate baseline renal dysfunction yielded results consistent with the overall trial compared with dose-adjusted warfarin. 9 Third, although patients with WRF had an increased rate of stroke or systemic embolism com- pared with those with SRF, this did not appear to depend on baseline CrCl or magnitude of WRF. This finding may reassure clinicians and their patients of the generalizability of the results when prescribing anticoagulants to this high-risk group. Taken together, these data suggest that rivaroxaban may have a better renal risk-benefit profile than warfarin in the setting of patients with WRF. This study also has some limitations. First, similar to other post hoc clinical trial observational analyses, there may be some unmeasured confounders that could explain the results. Second, because we included all additional creatinine measurements beyond that used in the study protocol to define our WRF cohort, this group is likely enriched with patients for whom clinicians were closely evaluating renal function, and findings may not apply to patients with WRF who did not receive frequent creatinine measurements. However, this likely reflects real-life clinical decision making when patients with WRF are monitored and therefore may be generally applicable to this population. Third, these results apply mainly to WRF patients who had a reduction of 20% in CrCl by Cockcroft-Gault, the estimating equation on which drug-dosing guidelines have historically been developed and that is consistent with the recommendation of the US Food and Drug Administration. 32 The calculation of CrCl, which includes patient weight, may be a less biased reflection of WRF compared with an absolute cutoff such as 0.3 mg/dL. 24 Our findings appear to be sensitive to the formula used to calculate glomerular filtration rate because the superiority of rivaroxaban could not be replicated with the CKD-EPI formula, although the directionality was consistent.
conclusions Among patients with on-treatment WRF, rivaroxaban was associated with lower rates of the primary end point of stroke and systemic embolism compared with warfarin without an increase in the composite bleeding end point. This study suggests not only that it is possible to safely anticoagulate patients with WRF without excessive bleeding but also that rivaroxaban is an attractive alternative to warfarin in patients with or at risk for WRF. Only the first follow-up CrCl value was used in defining groups for event rates, but all values were used in the models to generate HRs and P-values. 
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